Industry Snapshots:

• The market size of the worldwide vascular graft will surpass USD 3.85 billion in 2025, and by 2035, it is projected to reach USD 7.16 billion, growing at a CAGR of 6.4% during the forecast period.

• The vascular graft market is advancing steadily, surging by innovations in graft materials and designs and the rising prevalence of chronic artery diseases as coronary artery diseases (CAD) for example, in 2022, about 315 million people were estimated with CAD, and more than 600,000 coronary artery bypass surgery procedures were performed worldwide which represents the vital role of vascular grafts in cardiovascular treatment. Innovation in tissue-engineered, bioresorbable, and 3D-printed vascular grafts that enhance functionality of the vascular grafts which is being propelled by the increasing need for long-lasting and biocompatible grafts. Technological innovation continues to be the primary driver driving the worldwide vascular graft market, owing to developments as hybrid stent-grafts and decellularized scaffolds and minimally invasive surgeries.

• In January 2025, Bentley InnoMed GmbH has launched the BeGraft stent graft system designed for fenestrated endovascular aneurysm repair (FEVAR) procedures and includes a stent on a unique stepped balloon for easier deployment.

Growth Catalysts:

Increase in end-stage renal disease (ESRD) and hemodialysis cases: The demand for vascular grafts is escalated by the increasing proportion of hemodialysis patients and the rising prevalence of End-Stage Renal Disease (ESRD) which need long-term vascular access and hemodialysis procedures, which is frequently managed via arteriovenous (AV) grafts as 4.2 million people were estimated receiving dialysis globally in 2024, with 89% of them received hemodialysis. Strong and biocompatible graft materials are always needed because of this large patient population and the frequent need to repair or modify access grafts over time. As evidenced by the increasing incidence of ESRD brought on by chronic conditions like diabetes and hypertension, vascular grafts are critical to maintaining effective dialysis treatment worldwide.

Upsurge in organ transplantation: The rising number of organ transplantations is emerging as a significant driver for the vascular grafts market. For instance, Global Observatory on Donation and Transplantation reported that in 2023, more than 172,000 solid-organ transplants were performed worldwide as of 39% of living kidney transplants, 25% of actual donation after circulatory death (DCD), and 25% of living liver transplants which indicates huge requirement of vascular grafts to reconstruct donor vessels or repair recipient vasculature, ensuring optimal blood flow and reducing complications. Vascular grafts are positioned as a crucial product segment in contemporary surgical treatment as a result of this development, which expands the geographic basis for graft usage.

Industry Innovations:

Integration of heparin-coated and antithrombogenic-coated in vascular grafts: The introduction of heparin-coated and antithrombogenic surfaces in vascular grafts is an advancement which reduces blood clot formation and enhance graft patency, which is beneficial for patients in long-term vascular procedures like coronary artery bypass and hemodialysis. Heparin-coated grafts decrease the need for systemic anticoagulation therapy and lowering bleeding risks. For instance, W. L. Gore & Associates, Inc. developed PROPATEN® a vascular graft, designed with a heparin-bonded surface to improve blood compatibility and minimize thrombosis which offer higher long-term patency rates than traditional synthetic materials, enhancing surgical outcomes and patient safety. The benefits of heparin-bonded grafts also contribute to fewer hospital readmissions and better overall patient outcomes. Continued research and development in surface modification and regulatory expansion boost the vascular grafts technology in various management of the chronic conditions.

Advancements in the vascular grafts: bioengineered grafts: The development of bioengineered grafts that aligns with natural blood vessels is one of the unique advancements in the vascular grafts market. Biological components that support cell adhesion and tissue regeneration, such as collagen, elastin, and decellularized tissues, are used to construct these grafts. Bioengineered grafts have lower risks of infection and thrombosis and are biocompatible than conventional vascular grafts which promote long-term efficiency and functional integration into the host's vascular system by promoting the development of endothelial cells. For instance, Humacyte, Inc. designed, bioengineered human tissues at commercial scale and developed SYMVESS (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible.

Potential Opportunities 

Rising adoption of personalized and 3D-printed graft solutions: The market for vascular grafts have huge opportunities in the upcoming years due to the growing use of personalised and 3D-printed vascular grafts. These grafts will be made to fit unique anatomical and biomechanical needs owing to developments in additive manufacturing and patient-specific modeling, which will improve surgical accuracy and better health outcomes of the patients. Graft performance and long-term functionality will be improved by the use of robust and biocompatible printing materials. In the vascular grafts market, 3D-printed grafts will develop into a high-value product category that will accelerate technological distinction, surgeon adoption. This is in line with the global trend toward precision medicine and customized surgical solutions, which encourages partnerships between 3D printing companies and medical equipment manufacturers.

Synthetic-Biologic combination grafts as a market opportunity: The adoption of hybrid vascular grafts, which provide a chance to grow the vascular transplant industry by combining synthetic materials with biologic tissues. These grafts will combine the biocompatibility and regenerative qualities of biologic materials with the mechanical strength and persistence of synthetic grafts to address issues including thrombosis, infection, and decreased long-term patency associated with traditional transplants. The adaptability property of hybrid grafts results in to the extensive usage in trauma-related vascular repairs, coronary artery bypass, and peripheral artery reconstruction, among other therapies. The hybrid grafts will enable manufacturers to offer high-end, premium products that meet the rising requirement for safer and reliable surgical treatments, driving expansion.

Recent Industry Updates:

• In August 2025, The US FDA has approved the expansion of Aquedeon Medical's clinical trial for the Duett vascular graft system, which is designed for the surgical repair of aortic arch aneurysms and dissections and simplify the vascular anastomosis process.

• In March 2025, Cook Medical’s Zenith Alpha 2 (ZTA2) thoracic endovascular graft is now available throughout the United States. A company press release states ZTA2 is the first aortic device on the market that has evolved to accommodate CO2 flushing and has an approved flushing protocol.

Industry Outlook Scope:

By Graft Type

• Natural Graft

        o Autologous Grafts

        o Allografts

        o Xenografts

• Synthetic Graft

        o Polyurethane Vascular Grafts

        o Expanded Polytetrafluoroethylene Vascular Grafts

        o Polyester Vascular Grafts

        o Biosynthetic Vascular Grafts

• Biosynthetic Graft

By Product Type

• Peripheral Vascular Grafts

• Coronary Artery Bypass Grafts

• Endovascular Stent Grafts

• Hemodialysis Access Grafts

By Application

• Coronary Artery Disease

• Peripheral Artery Disease

• Aneurysm Repair

• Hemodialysis

• Vascular Trauma

By End-Users

• Hospitals

• Ambulatory Surgical Centers

• Dialysis Center

• Others (Specialty Clinics and Vascular Care Centers)

Category Insights:

By Graft Type

Synthetic graft holds the largest market share: The synthetic graft segment dominates the vascular graft market because of their great availability, consistent production, and long-term durability for large- and medium-diameter arteries, synthetic grafts such as polyester, ePTFE, and polyurethane types represent the largest section of the vascular graft market. They are preferred by hospitals and surgical facilities due to their dependability and convenience of storage, which guarantees their continuous usage in aortic, peripheral, and coronary surgeries.

Biosynthetic graft exhibits the fastest growth: The biosynthetic graft segment is witnessing the fastest growth in the vascular graft market due to biological compatibility and synthetic durability; biosynthetic grafts are the fastest-growing category and are perfect for high-risk patients and small-diameter veins. Bioactive coatings, tissue-engineered materials, and cell-seeded scaffolds are examples of innovations that increase healing, decrease thrombosis, and improve patency. 

By Applications

Coronary artery disease leads the market: The coronary artery disease segment holds the largest share of the vascular graft market due to the high incidence of heart disease and the widespread use of coronary artery bypass grafting (CABG), coronary artery disease (CAD) is the main use for vascular grafts; to reestablish blood flow, a variety of grafts are widely used, including small-diameter synthetic alternatives and autologous veins. 

Peripheral artery disease sees rapid adoption: The peripheral artery disease is the growing at fastest pace in the vascular graft market due to rising rates of diabetes, obesity, and vascular problems in older populations. Peripheral vascular grafts synthetic, biosynthetic, and xenografts are increasingly being used for limb bypass procedures. Innovations like minimally invasive procedures and small-diameter biosynthetic grafts, which enhance patient outcomes and drives the segment fastest growth.

Regional Dynamics:

North America holds the highest market share: The North America holds the largest share in the global vascular grafts market. North America's robust healthcare system and escalating rates of cardiovascular diseases necessitating surgery demand. For instance, The National Center for Biotechnology Information reports that about 400,000 coronary artery bypass graft (CABG) surgeries are performed annually in the US and demand for vascular grafts is increased with the number of grafts supplied which accounts for autologous grafts, biosynthetic grafts, and synthetic grafts. Other advancements and initiatives that help the North America vascular graft market include biodegradable and tissue-engineered grafts, off-the-shelf small-diameter grafts, surgical planning models with artificial intelligence (AI) and with reimbursement support, special vascular centers that enable growth, and government and institutional initiatives supporting cardiovascular research.

Asia Pacific exhibits fastest growth: The Asia Pacific region is witnessing the rapid growth in the vascular graft market due to the rising need for vascular grafts to perform increasingly complex vascular surgeries, bypass grafting and repairs. The demand has raised for vascular grafts due to the elder population, the increased incidence of diabetes and obesity, and the rise in the prevalence of peripheral vascular and cardiovascular disorders. Government of India analysed that organ transplantation is inclining and stated in 2024, there were over 18,900 organ transplants performed in India which indicates the rapidly growing medical infrastructure and surgical capacity in the country. Various government-led programs include; financial assistance for patients, more residency training for primary medical staff, public awareness initiatives focused on encouraging organ donation and better interplay between regions resulting in complex surgical procedures having greater accessibility. 

Industry Competition:

• Becton, Dickinson, and Company

• Medtronic

• Terumo

• Endologix

• Cook Medical

• W. L. Gore & Associates

• Boston Scientific Corp.

• Admedus Ltd.

• Maquet

• C.R. Bard

• LeMaitre vascular Inc.

What to Expect from Outlook:

1. Save time carrying out entry-level research by identifying the size, growth trends, major segments, and leading companies in the Global Vascular Graft Market.

2. Use PORTER’s Five Forces analysis to assess the competitive intensity and overall attractiveness of the Global Vascular Graft Market.

3. Profiles of leading companies provide insights into key players’ regional operations, strategies, financial results, and recent initiatives.

4. Add weight to presentations and pitches by understanding the future growth prospects of the Global Vascular Graft Market with a forecast for the decade by both market share (%) & revenue (USD Billion).